Camtek Ltd (CAMT) has an average rating of overweight and mean price target of $174.67, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our price target from $166 to $239, 16x our FY 28 (Jan.) EPS view, above DELL's three-year average (~11x) on AI upside. We raise our FY 27 EPS view by $0.31 to $12.80 and FY 28's by $0.49 to $14.91. Global AI data center spending continues to strengthen, and we expect DELL will continue capitalizing on this momentum as it builds its reputation in the AI server space. We also think server peer SMCI's recent export control issues could see some of its non-hyperscaler business shift toward DELL, providing upside to recent guidance, while recent takeover rumors (despite being denied by NVDA) highlight DELL's value as a critical infrastructure provider and provide further support for an above-historical multiple. The ongoing memory shortage remains a key risk, but with supply fully secured to support FY 27 guidance, we doubt a significant hit to the company's near-term margin outlook. We expect its relationship with memory makers will allow for favorable supply allocation vs. peers next year as well.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vale posted solid Q1 2026 (operating) results, with iron ore production of 69.7Mt (+3.0% Y/Y) and energy transition metals delivering double-digit growth, including copper at 102.3kt (+12.5% Y/Y) and nickel at 49.3kt (+12.3% Y/Y). The performance marked multiyear highs across core assets, with S11D achieving another record and Southeastern System surging 19.2% driven by Capanema's ramp-up. We view the operational momentum as validation of Vale's capital strategy and positioning for long-term value creation in energy transition metals. Management maintained 2026 guidance, expecting upper end of 335Mt-345Mt iron ore targets as Capanema reaches full capacity. Copper realizations surged 47.8% Y/Y to $13,143/t while iron ore premiums expanded 29.2%, demonstrating portfolio optimization benefits. We believe base metals are becoming increasingly important value drivers as Novo Carajas advances, though key watch items include project execution and iron ore premium sustainability.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target at $21, based on 8.8x our FY 27 (Feb.) EPS of $2.38 (raised from $2.36; FY 28 initiated at $2.64). This multiple is near its long-term mean of 9.1x but remains a discount to its closest publicly-traded peer Kroger (~13x). Pharmacy headwinds from the Inflation Reduction Act are weighing on identical sales this fiscal year, though they are benefiting margins through a mix shift toward higher-margin generics. Margins should also improve with better digital profitability, easing GLP-1 pressure, and ongoing productivity initiatives. We expect identical sales growth to remain pressured in May-Q due to egg deflation, with both growth and profitability improving in subsequent quarters. We also believe ACI's investments in value, including lower prices and targeted promotions, should begin to drive an improvement in core grocery trends as the year progresses. Our Buy view reflects double-digit total shareholder return potential, including share repurchases and a ~4% dividend yield.